Natera partners with Diakonos Oncology to use Signatera in refractory melanoma trial

Natera, Inc.

Natera, Inc.

NTRA

0.00
  • Natera entered a collaboration with Diakonos Oncology to use Signatera to track molecular response in refractory melanoma patients.
  • Signatera will measure circulating tumor DNA at multiple timepoints during and following treatment in Diakonos’ DOC-RM Phase I/II trial.
  • The trial evaluates DOC1021 (dubodencel), a personalized dendritic cell investigational therapy with FDA Fast Track designation in unresectable or metastatic cutaneous melanoma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260529102657) on May 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.